PNC-27
Chimeric p53-Penetratin Anticancer Peptide | HDM-2 Targeting
On this page
What is PNC-27?
PNC-27 is a lab-made chimeric peptide — two peptide fragments joined together — designed by researchers to study a specific cell-membrane protein found on cancer cells grown in the lab. All of the published evidence comes from in-vitro (test-tube and cell-culture) and animal studies, not human clinical trials, and the FDA has warned against products marketed as containing it. It's sold here strictly as a research chemical for laboratory study, not for use in people or animals, and it is not an approved or proven cancer treatment.
Key terms:
PNC-27 is a chimeric peptide (p53 domain + penetratin mrp).
PNC-27 is a lab-made chimeric anticancer peptide of 32 amino acids. Dr. Matthew Pincus and Dr. Joseph Michl developed it in 2000 at SUNY Downstate Medical Center using supercomputer modeling. It joins the HDM-2 binding domain of the p53 tumor suppressor protein (residues 12-26) to a membrane-penetrating peptide (MRP) derived from the Antennapedia penetratin sequence. In studies it selectively killed cancer cells: it binds HDM-2 (MDM2) on their membranes and forms transmembrane pores, causing rapid necrotic cell death — a process termed 'poptosis.' Normal cells, which lack membrane-associated HDM-2, were unaffected. A 2024 study revealed a secondary mechanism: PNC-27 also enters cells and selectively disrupts mitochondrial membranes while sparing lysosomes. Preclinical studies reported efficacy against pancreatic, breast, melanoma, leukemia, ovarian, cervical, and other cancers.
Key research areas
- Selective cancer cell killing via HDM-2 membrane targeting and mitochondrial disruption
- Demonstrated efficacy against multiple cancer types in preclinical studies (pancreatic, breast, melanoma, leukemia, ovarian, cervical)
- Normal cells unaffected
- Synergy with paclitaxel and ketone bodies documented
Researched dosing
This table reflects dosing used in community research protocols for PNC-27 — none of this is clinically validated, and it's presented as research-methodology reference only, not usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Standard study protocol | 100-500mcg | Once daily, subcutaneous | Subcutaneous (abdomen) |
| Starting dose | 100mcg | Once daily, subcutaneous | Subcutaneous |
Commonly cycled 12 weeks on, 0+ weeks off.
How it works
At the cell level, PNC-27 research looks at how the peptide binds a specific protein (HDM-2) found on the outer membrane of cancer cells grown in culture, forming pores in that membrane — this has only been observed in vitro and in animal models, not in human patients.
PNC-27 contains the p53 HDM-2-binding domain (residues 12-26) linked to a membrane-penetrating peptide. It binds HDM-2 overexpressed on cancer cell membranes, forming oligomeric transmembrane pore complexes that cause rapid necrotic cell death ('poptosis'). A secondary mechanism involves direct mitochondrial membrane disruption. Normal cells lack membrane HDM-2 and are unaffected, regardless of p53 mutation status.
Molecular data
These figures — molecular weight, chain length, sequence — are the chemistry ID researchers use to confirm a PNC-27 sample's identity; it's built by joining two peptide fragments into one chimeric chain.
- Weight
- 4031.72 Da
- Length
- 32 amino acids
- Type
- Chimeric peptide (p53 domain + penetratin MRP)
Research applications
This section summarizes the research areas that in-vitro and animal studies have investigated for PNC-27 — a summary of published preclinical research, not medical claims about people, and PNC-27 is not an approved or proven cancer treatment.
Anticancer
Kills cancer cells from multiple lineages (pancreatic, breast, melanoma, leukemia, ovarian, cervical) while sparing normal fibroblasts, lymphocytes, stem cells, and epithelial cells. Unlike intracellular HDM-2 inhibitors, PNC-27 targets membrane-associated HDM-2 and works regardless of p53 mutation status. Both plasma membrane pore formation and mitochondrial membrane disruption contribute to cancer cell death (2024 discovery). Paclitaxel-surviving ovarian cancer cells upregulate membrane HDM-2, increasing susceptibility to PNC-27 — documented synergy via isobologram analysis.
Metabolic
Emerging research on metabolic interactions including synergy with ketone bodies (BHB, Acetoacetate) in cancer cell killing models.
Dosage reference
- Doses used in research
- 100–500 mcg
- Frequency in studies
- Once daily
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Preclinical data only — no established human efficacy timeline
- Storage
- Lyophilized: -20°C to -80°C | Reconstituted: 2-8°C
- Cycle length
- 8-12 weeks (community protocol, not clinically validated)
- Break between cycles
- No established protocol — insufficient data
Interactions
This list shows which other compounds researchers have studied alongside PNC-27 in preclinical models, and why.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried PNC-27 powder into a liquid research solution using bacteriostatic water.
- Clean work area and hands thoroughly
- Calculate required BAC water volume using calculator below
- Draw BAC water into syringe
- Inject slowly down vial side (not directly onto powder)
- Gently swirl until dissolved (never shake)
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: -20°C to -80°C, use within Extended — store long-term at -20°C to -80°C
Reconstituted: 2-6°C, use within 28 days
Open the PNC-27 reconstitution calculatorQuality indicators
These are the checks — purity testing, appearance, source verification — researchers use to confirm a PNC-27 sample is correctly identified; the FDA has specifically warned about contaminated PNC-27 products, so third-party testing is essential.
FDA Warning Issued - FDA has explicitly warned consumers to avoid PNC-27 products due to contamination and lack of approval
No Verified Human Trials - Claims of clinical trials exist in secondary sources but no NCT numbers or peer-reviewed results found
Third-Party Testing Required - Verify purity (>98% HPLC), sterility, and endotoxin levels through independent certificate of analysis (COA)
Lyophilized Powder Form - Should be supplied as white lyophilized powder — verify appearance matches expectations
Nebulized/Inhalable Products - FDA specifically cited contaminated inhalable PNC-27 products — avoid this route entirely
Cure Claims - Any vendor claiming PNC-27 is a proven cancer cure is making unsubstantiated claims — this is a research compound only
What to expect
This timeline reflects observations from in-vitro and preclinical research only — there is no established human timeline, because PNC-27 has not been tested in human clinical trials.
Community protocols suggest 8-12 week cycles; preclinical data shows cancer cell death occurs within 90 minutes at effective concentrations in vitro. No established human efficacy timeline.
Safety notes
This section covers regulatory warnings and handling cautions for PNC-27 — the FDA has explicitly warned against PNC-27 products, and this compound should never replace an approved cancer treatment or medical guidance from a qualified oncologist.
- Should never replace FDA-approved cancer treatments
- Discuss with a qualified oncologist before any consideration of use
- Avoid nebulized/inhalable forms (contamination risk cited by FDA)
- Source quality is critical — third-party testing essential
- NOT FDA approved — FDA has issued explicit warnings against PNC-27 use
- FDA found bacterial contamination (Variovorax paradoxus) in marketed PNC-27 products
- No verified human clinical trial data published in peer-reviewed journals
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
First major publication demonstrating PNC-27 adopts a p53-like structure when binding membrane HDM-2, forms transmembrane pores visualized by electron microscopy, and kills pancreatic, breast, and melanoma cancer cells while sparing normal fibroblasts.
Demonstrated PNC-27 remains intact during membranolysis. Neither the p53 domain alone, the MRP alone, nor both domains uncoupled could induce cancer cell death — the chimeric linkage is essential for activity.
Extended PNC-27's selectivity to non-solid tumors. Killed K562 leukemia cells at nearly 100% while showing no cytotoxicity to normal murine lymphocytes at any tested concentration. Confirmed necrotic (not apoptotic) cell death.